SCHEMBL6735699

SCHEMBL6735699

CS(=O)(=O)c1c(F)cc(-c2cscc2-c2ccc(C(F)(F)F)cc2)cc1F

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 9/20 0.49
PTGS1 P23219 3/20 0.42
KIF11 P52732 5/20 0.42
ALOX5AP P20292 2/20 0.41
FEN1 P39748 2/20 0.41
APP P05067 1/20 0.41
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6728546 0.85 PTGS2 (0.67) PTGS2PTGS1
SCHEMBL6733128 0.85 PTGS2 (0.43) PTGS2PTGS1ALOX5APFEN1SCN9A
SCHEMBL6733630 0.85 PTGS2 (0.51) PTGS2PTGS1KIF11ALOX5APFEN1
SCHEMBL6734126 0.84 PTGS2 (0.62) PTGS2PTGS1
SCHEMBL6739763 0.84 PTGS2 (0.53) PTGS2PTGS1
SCHEMBL6735421 0.83 PTGS2 (0.51) PTGS2PTGS1
SCHEMBL6732633 0.83 PTGS2 (0.49) PTGS2PTGS1KIF11SCN5ASCN9A
SCHEMBL6739997 0.82 PTGS2 (0.53) PTGS2PTGS1
SCHEMBL6733892 0.82 PTGS2 (0.59) PTGS2PTGS1
SCHEMBL6732138 0.82 KIF11 (0.46) PTGS2PTGS1KIF11SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885KIF11 4765/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885KIF11 4765/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885KIF11 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.